Skip to main content
Premium Trial:

Request an Annual Quote

ChanTest, FDA Partner on Cardiac Safety Assays

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ChanTest is collaborating with the US Food and Drug Administration to develop assays to improve prediction of cardiac safety, the company announced on Thursday.

Under the deal with the FDA's Center for Drug Evaluation and Research, the Cleveland-based firm will develop non-clinical assays, databases, and computational models for assessing the risk of serious cardiac events associated with drug-induced QT prolongation. Research will also be done to identify gaps in current safety testing methods for new drugs.

Terms of the deal were not disclosed.

In a statement, ChanTest said that the hERG assay, a primary method of classifying investigational drugs with the potential to prolong the QT interval, is generally viewed as being insufficiently sensitive and specific to predict the clinical risk of QT prolongation and serious ventricular arrhythmia accurately across all chemical and drug classes. While seeking to identify gaps in current safety testing, the collaboration will improve understanding of the cellular basis for serious clinical events associated with QT prolongation, it said.

ChanTest offers ion channel and GPCR screening services to research and drug discovery and development customers.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.